Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 12/20 | 0.39 |
| ▸ | PPARG | P37231 | 9/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ELAVL1 | Q15717 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL382955 | 0.92 | PPARA (0.42) | PPARAPPARGADORA1SLC6A3MAPT | |
| SCHEMBL12536119 | 0.85 | ADORA1 (0.38) | PPARAPPARGADORA1SLC6A3MAPT | |
| SCHEMBL12535121 | 0.85 | ADORA1 (0.41) | PPARAPPARGADORA1SLC6A3MAPT | |
| SCHEMBL12535500 | 0.83 | ADORA1 (0.43) | PPARAPPARGADORA1SLC6A3MAPT | |
| SCHEMBL10195690 | 0.82 | PPARA (0.42) | PPARAPPARGMAPTKDM4EALDH1A1 | |
| SCHEMBL12535546 | 0.82 | ADORA1 (0.37) | PPARAPPARGADORA1SLC6A3MAPT | |
| SCHEMBL12910844 | 0.81 | ADORA1 (0.38) | PPARAPPARGADORA1SLC6A3MAPT | |
| SCHEMBL1933429 | 0.80 | ADORA1 (0.43) | PPARAPPARGADORA1SLC6A3MAPT | |
| SCHEMBL12535550 | 0.78 | ADORA1 (0.38) | PPARAPPARGADORA1SLC6A3MAPT | |
| SCHEMBL12535538 | 0.78 | ADORA1 (0.48) | PPARGADORA1SLC6A3MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003845-A1 | SUBSTITUTED AZABICYCLIC COMPOUNDS AND THE USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003845-A1 | SUBSTITUTED AZABICYCLIC COMPOUNDS AND THE USE THEREOF | PPIP5K2, TPMT, PNPO | PPARA 51/4885PPARG 24/4885ADORA1 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.